137 related articles for article (PubMed ID: 26188109)
1. An oral cathepsin K inhibitor ONO-5334 inhibits N-terminal and C-terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women.
Tanaka M; Hashimoto Y; Hasegawa C
Bone; 2015 Dec; 81():178-185. PubMed ID: 26188109
[TBL] [Abstract][Full Text] [Related]
2. Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.
Nagase S; Hashimoto Y; Small M; Ohyama M; Kuwayama T; Deacon S
Br J Clin Pharmacol; 2012 Dec; 74(6):959-70. PubMed ID: 22533981
[TBL] [Abstract][Full Text] [Related]
3. Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
Eastell R; Dijk DJ; Small M; Greenwood A; Sharpe J; Yamada H; Yuba M; Tanimoto M; Deacon S
Osteoporos Int; 2016 Jan; 27(1):309-18. PubMed ID: 26446770
[TBL] [Abstract][Full Text] [Related]
4. Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns.
Tanaka M; Hashimoto Y; Sekiya N; Honda N; Deacon S; Yamamoto M
J Bone Miner Metab; 2014 Jul; 32(4):447-54. PubMed ID: 24114194
[TBL] [Abstract][Full Text] [Related]
5. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.
Tanaka M; Hashimoto Y; Hasegawa C; Deacon S; Eastell R
BMC Musculoskelet Disord; 2017 Jun; 18(1):267. PubMed ID: 28629344
[TBL] [Abstract][Full Text] [Related]
6. The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorption.
Taga M; Uemura T; Minaguchi H
J Endocrinol Invest; 1998 Mar; 21(3):154-9. PubMed ID: 9591210
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.
Hasegawa C; Ohno T; Umemura T; Honda N; Ohyama M; Nagase S; Small M; Deacon S; Ogawa M; Ieiri I
J Clin Pharmacol; 2014 Jan; 54(1):23-34. PubMed ID: 24115072
[TBL] [Abstract][Full Text] [Related]
9. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption.
Clemens JD; Herrick MV; Singer FR; Eyre DR
Clin Chem; 1997 Nov; 43(11):2058-63. PubMed ID: 9365389
[TBL] [Abstract][Full Text] [Related]
10. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
11. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
Stoch SA; Zajic S; Stone JA; Miller DL; van Bortel L; Lasseter KC; Pramanik B; Cilissen C; Liu Q; Liu L; Scott BB; Panebianco D; Ding Y; Gottesdiener K; Wagner JA
Br J Clin Pharmacol; 2013 May; 75(5):1240-54. PubMed ID: 23013236
[TBL] [Abstract][Full Text] [Related]
12. New biochemical markers of bone resorption in the study of postmenopausal osteoporosis.
de la Piedra C; Traba ML; Dominguez Cabrera C; Sosa Henríquez M
Clin Chim Acta; 1997 Sep; 265(2):225-34. PubMed ID: 9385464
[TBL] [Abstract][Full Text] [Related]
13. Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women.
Nagase S; Ohyama M; Hashimoto Y; Small M; Sharpe J; Manako J; Kuwayama T; Deacon S
J Bone Miner Metab; 2015 Jan; 33(1):93-100. PubMed ID: 24458199
[TBL] [Abstract][Full Text] [Related]
14. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men.
Fall PM; Kennedy D; Smith JA; Seibel MJ; Raisz LG
Osteoporos Int; 2000; 11(6):481-5. PubMed ID: 10982162
[TBL] [Abstract][Full Text] [Related]
15. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.
Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
Bone; 2011 Dec; 49(6):1351-6. PubMed ID: 21982869
[TBL] [Abstract][Full Text] [Related]
16. Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
Lindström E; Rizoska B; Henderson I; Terelius Y; Jerling M; Edenius C; Grabowska U
J Transl Med; 2018 May; 16(1):125. PubMed ID: 29743078
[TBL] [Abstract][Full Text] [Related]
17. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
[TBL] [Abstract][Full Text] [Related]
18. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I.
Reginster JY; Henrotin Y; Christiansen C; Gamwell-Henriksen E; Bruyere ; Collette J; Christgau S
Calcif Tissue Int; 2001 Sep; 69(3):130-7. PubMed ID: 11683527
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover.
Srivastava AK; Libanati C; Hohmann O; Kriegman A; Baylink DJ
Calcif Tissue Int; 2004 Dec; 75(6):477-81. PubMed ID: 15365658
[TBL] [Abstract][Full Text] [Related]
20. Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys.
Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
Bone; 2014 Aug; 65():1-8. PubMed ID: 24784023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
